Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 74, Issue 2

Viral vectors: design and delivery for small RNA Free

Abstract

RNA interference regulates gene expression by selectively silencing target genes through the introduction of small RNA molecules, such as microRNA, small interfering RNA and short hairpin RNA. These molecules offer significant therapeutic potential for diverse human ailments like cancer, viral infections and neurodegenerative disorders. Whilst non-viral vectors like nanoparticles have been extensively explored for delivering these RNAs, viral vectors, with superior specificity and delivery efficiency, remain less studied. This review examines current viral vectors for small RNA delivery, focusing on design strategies and characteristics. It compares the advantages and drawbacks of each vector, aiding readers in selecting the optimal one for small RNA delivery.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): DNA viruses , Drosha , gene silencing , RNA viruses , small RNA and viral vector
Funding
This study was supported by the:
  • Universiti Putra Malaysia (Award Geran Putra Berimpak 9727100)
    • Principal Award Recipient: SuetLin Chia
© 2025 The Authors
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001972
2025-02-14
2025-12-11

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/jmm/74/2/jmm001972.html?itemId=/content/journal/jmm/10.1099/jmm.0.001972&mimeType=html&fmt=ahah

References

  1. Ecker JR, Davis RW. Inhibition of gene expression in plant cells by expression of antisense RNA. Proc Natl Acad Sci USA 1986; 83:5372–5376 [View Article]
     [Google Scholar]
  2. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806–811 [View Article] [PubMed]
     [Google Scholar]
  3. Lam JKW, Chow MYT, Zhang Y, Leung SWS. siRNA Versus miRNA as Therapeutics for Gene Silencing. Mol Ther Nucleic Acids 2015; 4:e252 [View Article] [PubMed]
     [Google Scholar]
  4. Zhou F, Malik FA, jun YH, hua LX, Roy B et al. Application of short hairpin rnas (shrnas) to study gene function in mammalian systems. African J Biotechnol 2010; 9:9089–9091
     [Google Scholar]
  5. RNAi FRE. RNAi. RNA methodol 2010539–560 [View Article]
     [Google Scholar]
  6. Neumeier J, Meister G. siRNA Specificity: RNAi Mechanisms and Strategies to Reduce Off-Target Effects. Front Plant Sci 2020; 11:526455 [View Article] [PubMed]
     [Google Scholar]
  7. Fakhr E, Zare F, Teimoori-Toolabi L. Precise and efficient siRNA design: A key point in competent gene silencing. Cancer Gene Ther 2016; 23:73–82 [View Article] [PubMed]
     [Google Scholar]
  8. Sliva K, Schnierle BS. Selective gene silencing by viral delivery of short hairpin RNA. Virol J 2010; 7:1–11 [View Article] [PubMed]
     [Google Scholar]
  9. Yang N. An overview of viral and nonviral delivery systems for microRNA. Int J Pharm Investig 2015; 5:179–181 [View Article] [PubMed]
     [Google Scholar]
  10. Park SY, Kim KH, Kim S, Lee YM, Seol YJ. BMP-2 Gene Delivery-Based Bone Regeneration in Dentistry. Pharmaceutics 2019; 11:393 [View Article] [PubMed]
     [Google Scholar]
  11. Fu Y, Chen J, Huang Z. Recent progress in microRNA-based delivery systems for the treatment of human disease. ExRNA 2019; 1:1–14 [View Article]
     [Google Scholar]
  12. Ramamoorth M, Narvekar A. Non viral vectors in gene therapy- an overview. J Clin Diagn Res 2015; 9:GE01–6 [View Article] [PubMed]
     [Google Scholar]
  13. Sheng P, Flood KA, Xie M. Short Hairpin RNAs for Strand-Specific Small Interfering RNA Production. Front Bioeng Biotechnol 2020; 8:940 [View Article] [PubMed]
     [Google Scholar]
  14. Herrera-Carrillo E, Liu YP, Berkhout B. Improving miRNA Delivery by Optimizing miRNA Expression Cassettes in Diverse Virus Vectors. Hum Gene Ther Methods 2017; 28:177–190 [View Article] [PubMed]
     [Google Scholar]
  15. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol 2018; 9:402 [View Article] [PubMed]
     [Google Scholar]
  16. Aguiar S, van der Gaag B, Cortese FAB. RNAi mechanisms in Huntington’s disease therapy: siRNA versus shRNA. Transl Neurodegener 2017; 6:30 [View Article] [PubMed]
     [Google Scholar]
  17. Rao DD, Vorhies JS, Senzer N, Nemunaitis J. siRNA vs. shRNA: similarities and differences. Adv Drug Deliv Rev 2009; 61:746–759 [View Article] [PubMed]
     [Google Scholar]
  18. Colón-Thillet R, Jerome KR, Stone D. Optimization of AAV vectors to target persistent viral reservoirs. Virol J 2021; 18:85 [View Article] [PubMed]
     [Google Scholar]
  19. Liu J, Seol DW. Helper virus-free gutless adenovirus (HF-GLAd): a new platform for gene therapy. BMB Rep 2020; 53:565–575 [View Article] [PubMed]
     [Google Scholar]
  20. Andersson MG, Haasnoot PCJ, Xu N, Berenjian S, Berkhout B et al. Suppression of RNA interference by adenovirus virus-associated RNA. J Virol 2005; 79:9556–9565 [View Article] [PubMed]
     [Google Scholar]
  21. Tiscornia G, Singer O, Verma IM. Design and cloning of lentiviral vectors expressing small interfering RNAs. Nat Protoc 2006; 1:234–240 [View Article] [PubMed]
     [Google Scholar]
  22. Lund PE, Hunt RC, Gottesman MM, Kimchi-Sarfaty C. Pseudovirions as vehicles for the delivery of sirna. Pharm Res 2010; 27:400–420
     [Google Scholar]
  23. Aguirre AI, Epstein AL, Jerusalinsky DA. Using herpes simplex virus type 1-based amplicon vectors for neuroscience research and gene therapy of neurologic diseases. Mol Stat Tech Behav Neural Res 2018445–477 [View Article]
     [Google Scholar]
  24. Epstein AL. HSV-1-derived amplicon vectors: recent technological improvements and remaining difficulties - a review. Mem Inst Oswaldo Cruz 2009; 104:399–410
     [Google Scholar]
  25. Lin S-Y, Chen G-Y, Hu Y-C. Recent patents on the baculovirus systems. Recent Pat Biotechnol 2011; 5:1–11
     [Google Scholar]
  26. Anker SC, Szczeponik MG, Dessila J, Dittus K, Engeland CE et al. Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference. Viruses 2023; 15:308 [View Article] [PubMed]
     [Google Scholar]
  27. Honda T, Yamamoto Y, Daito T, Matsumoto Y, Makino A et al. Long-term expression of miRNA for RNA interference using a novel vector system based on a negative-strand RNA virus. Sci Rep 2016; 6:26154 [View Article] [PubMed]
     [Google Scholar]
  28. Langlois RA, Shapiro JS, Pham AM, tenOever BR. In vivo delivery of cytoplasmic RNA virus-derived miRNAs. Mol Ther 2012; 20:367–375 [View Article] [PubMed]
     [Google Scholar]
  29. Sano M, Nakasu A, Ohtaka M, Nakanishi M. A Sendai Virus-Based Cytoplasmic RNA Vector as A Novel Platform for Long-Term Expression of MicroRNAs. Mol Ther Methods Clin Dev 2019; 15:371–382 [View Article] [PubMed]
     [Google Scholar]
  30. Baltusnikas J, Satkauskas S, Lundstrom K. Constructing RNA Viruses for Long-Term Transcriptional Gene Silencing. Trends Biotechnol 2019; 37:20–28 [View Article] [PubMed]
     [Google Scholar]
  31. Varble A, Chua MA, Perez JT, Manicassamy B, García-Sastre A et al. Engineered RNA viral synthesis of microRNAs. Proc Natl Acad Sci USA 2010; 107:11519–11524 [View Article]
     [Google Scholar]
  32. Schmid S, Zony LC. BR A versatile RNA vector for delivery of coding and noncoding RNAs. J Virol 2014; 88:2333–2336 [View Article] [PubMed]
     [Google Scholar]
  33. Rouha H, Thurner C, Mandl CW. Functional microRNA generated from a cytoplasmic RNA virus. Nucleic Acids Res 2010; 38:8328–8337 [View Article] [PubMed]
     [Google Scholar]
  34. Shapiro JS, Varble A, Pham AM, Tenoever BR. Noncanonical cytoplasmic processing of viral microRNAs. RNA 2010; 16:2068–2074 [View Article] [PubMed]
     [Google Scholar]
  35. Manjunath N, Wu H, Subramanya S, Shankar P. Lentiviral delivery of short hairpin RNAs. Adv Drug Deliv Rev 2009; 61:732–745 [View Article] [PubMed]
     [Google Scholar]
  36. Dasgupta I, Chatterjee A. Recent Advances in miRNA Delivery Systems. Methods Protoc 2021; 4:4–10 [View Article] [PubMed]
     [Google Scholar]
  37. Tolmachov O, Tolmachova T, Al-Allaf FA, Tolmachov O, Tolmachova T et al. Designing lentiviral gene vectors. Viral Gene Ther Epub ahead of print 2011 [View Article]
     [Google Scholar]
  38. Abordo-Adesida E, Follenzi A, Barcia C, Sciascia S, Castro MG et al. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. Hum Gene Ther 2005; 16:741–751 [View Article] [PubMed]
     [Google Scholar]
  39. Denning W, Das S, Guo S, Xu J, Kappes JC et al. Optimization of the transductional efficiency of lentiviral vectors: effect of sera and polycations. Mol Biotechnol 2013; 53:308–314 [View Article] [PubMed]
     [Google Scholar]
  40. Schlimgen R, Howard J, Wooley D, Thompson M, Baden LR et al. Risks Associated With Lentiviral Vector Exposures and Prevention Strategies. J Occup Environ Med 2016; 58:1159–1166 [View Article] [PubMed]
     [Google Scholar]
  41. Zhang L, Chang L, Xu J, Meyers CA, Yan N et al. Frontal Bone Healing Is Sensitive to Wnt Signaling Inhibition via Lentiviral-Encoded Beta-Catenin Short Hairpin RNA. Tissue Eng Part A 2018; 24:1742–1752 [View Article] [PubMed]
     [Google Scholar]
  42. Asadi Samani L, Saffar B, Mokhtari A, Arefian E. Lentivirus expressing shRNAs inhibit the replication of contagious ecthyma virus by targeting DNA polymerase gene. BMC Biotechnol 2020; 20:18 [View Article] [PubMed]
     [Google Scholar]
  43. Zhou C, Zhang L, Xu P. Growth inhibition and chemo‑radiosensitization of esophageal squamous cell carcinoma by survivin‑shRNA lentivirus transfection. Oncol Lett 2018; 16:4813–4820 [View Article]
     [Google Scholar]
  44. Wold WSM, Toth K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther 2013; 13:421–433 [View Article] [PubMed]
     [Google Scholar]
  45. Kossila M, Jauhiainen S, Laukkanen MO, Lehtolainen P, Jääskeläinen M et al. Improvement in adenoviral gene transfer efficiency after preincubation at +37 degrees C in vitro and in vivo. Mol Ther 2002; 5:87–93 [View Article] [PubMed]
     [Google Scholar]
  46. Mowa MB, Crowther C, Arbuthnot P. Therapeutic potential of adenoviral vectors for delivery of expressed RNAi activators. Expert Opin Drug Deliv 2010; 7:1373–1385 [View Article] [PubMed]
     [Google Scholar]
  47. Cerullo V, Koski A, Vähä-Koskela M, Hemminki A. Chapter eight--Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans. Adv Cancer Res 2012; 115:265–318 [View Article] [PubMed]
     [Google Scholar]
  48. Tessarollo NG, Domingues ACM, Antunes F, Luz JCDS da, Rodrigues OA et al. Nonreplicating adenoviral vectors: Improving tropism and delivery of cancer gene therapy. Cancers 2021; 13:1863 [View Article] [PubMed]
     [Google Scholar]
  49. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6 Suppl 1:S164–71 [View Article] [PubMed]
     [Google Scholar]
  50. Vannucci L, Lai M, Chiuppesi F, Ceccherini-Nelli L, Pistello M. Viral vectors: a look back and ahead on gene transfer technology. New Microbiol 2013; 36:1–22 [PubMed]
     [Google Scholar]
  51. He N, Zhang X, Xie P, He J, Lv Z. Inhibition of posterior capsule opacification by adenovirus-mediated delivery of short hairpin RNAs targeting TERT in a rabbit model. Curr Eye Res 2023; 48:618–626 [View Article]
     [Google Scholar]
  52. Kita Y, Go T, Nakashima N, Liu D, Tokunaga Y et al. Inhibition of cell-surface molecular GPR87 with GPR87-suppressing adenoviral vector disturb tumor proliferation in lung cancer cells. Anticancer Res 2020; 40:733–741 [View Article] [PubMed]
     [Google Scholar]
  53. Scholz J, Weil PP, Pembaur D, Koukou G, Aydin M et al. An adenoviral vector as a versatile tool for delivery and expression of miRNAs. Viruses 2022; 14:1–18 [View Article] [PubMed]
     [Google Scholar]
  54. Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther - Methods Clin Dev 2018; 8:87–104 [View Article]
     [Google Scholar]
  55. Kim HS, Hwang G-H, Lee HK, Bae T, Park S-H et al. CReVIS-Seq: A highly accurate and multiplexable method for genome-wide mapping of lentiviral integration sites. Mol Ther Methods Clin Dev 2021; 20:792–800 [View Article] [PubMed]
     [Google Scholar]
  56. Shin JH, Yue Y, Duan D. Recombinant adeno-associated viral vector production and purification. Methods Mol Biol 2012; 798:267–284 [View Article] [PubMed]
     [Google Scholar]
  57. Ryu WS. Virus Vectors. Mol Virol Hum Pathog Viruses 2017263–275 [View Article]
     [Google Scholar]
  58. Kiwanuka E, Hackl F, Nowinski D, Eriksson E. Molecular and gene therapies for wound repair. Adv Wound Repair Ther 2011395–415 [View Article]
     [Google Scholar]
  59. Lu Y, He W, Huang X, He Y, Gou X et al. Strategies to package recombinant adeno-associated virus expressing the N-terminal gasdermin domain for tumor treatment. Nat Commun 2021; 12:7155 [View Article] [PubMed]
     [Google Scholar]
  60. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov 2019; 18:358–378 [View Article] [PubMed]
     [Google Scholar]
  61. Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med 2022; 8:2746
     [Google Scholar]
  62. Maurya S, Sarangi P, Jayandharan GR. Safety of Adeno-associated virus-based vector-mediated gene therapy—impact of vector dose. Cancer Gene Ther 2022; 29:1305–1306 [View Article]
     [Google Scholar]
  63. Ellis BL, Hirsch ML, Barker JC, Connelly JP, Steininger RJ 3rd et al. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J 2013; 10:1–10 [View Article] [PubMed]
     [Google Scholar]
  64. Srivastava A, Mallela KMG, Deorkar N, Brophy G. Manufacturing challenges and rational formulation development for AAV viral vectors. J Pharm Sci 2021; 110:2609–2624 [View Article] [PubMed]
     [Google Scholar]
  65. Valdor M, Wagner A, Röhrs V, Berg J, Fechner H et al. RNA interference-based functional knockdown of the voltage-gated potassium channel Kv7.2 in dorsal root ganglion neurons after in vitro and in vivo gene transfer by adeno-associated virus vectors. Mol Pain 2018; 14:1744806917749669 [View Article] [PubMed]
     [Google Scholar]
  66. Gao J, Guo Y, Chen Y, Zhou J, Liu Y et al. Adeno-associated virus 9-mediated RNA interference targeting SOCS3 alleviates diastolic heart failure in rats. Gene 2019; 697:11–18 [View Article] [PubMed]
     [Google Scholar]
  67. Marconi P, Argnani R, Epstein AL, Manservigi R. HSV as a vector in vaccine development and gene therapy; 2013 https://www.ncbi.nlm.nih.gov/books/NBK7024/ accessed 22 April 2023
  68. Lentz TB, Gray SJ, Samulski RJ. Viral vectors for gene delivery to the central nervous system. Neurobiol Dis 2012; 48:179–188 [View Article] [PubMed]
     [Google Scholar]
  69. Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H et al. Oncolytic herpes simplex virus-based therapies for cancer. Cells 2021; 10:1541 [View Article] [PubMed]
     [Google Scholar]
  70. Sena-Esteves M, Saeki Y, Fraefel C, Breakefield XO. HSV-1 amplicon vectors--simplicity and versatility. Mol Ther 2000; 2:9–15 [View Article] [PubMed]
     [Google Scholar]
  71. Hunter JE, Ramos L, Wolfe JH. Viral vectors in the CNS. Neurosci Biobehav Psychol 2017179–188 [View Article]
     [Google Scholar]
  72. Fernández-Frías I, Pérez-Luz S, Díaz-Nido J. Enhanced production of herpes simplex virus 1 amplicon vectors by gene modification and optimization of packaging cell growth medium. Mol Ther Methods Clin Dev 2020; 17:491–496 [View Article] [PubMed]
     [Google Scholar]
  73. Grant KG. n.d. Production and purification of highly replication defective HSV-1 based gene therapy vectors.
  74. Hong C-S, Goins WF, Goss JR, Burton EA, Glorioso JC. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer’s disease-related amyloid-β peptide in vivo. Gene Ther 2006; 13:1068–1079 [View Article]
     [Google Scholar]
  75. Anesti AM, Simpson GR, Price T, Pandha HS, Coffin RS. Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo. BMC Cancer 2010; 10:486 [View Article] [PubMed]
     [Google Scholar]
  76. Matilainen H, Rinne J, Gilbert L, Marjomäki V, Reunanen H et al. Baculovirus entry into human hepatoma cells. J Virol 2005; 79:15452–15459 [View Article] [PubMed]
     [Google Scholar]
  77. Nasimuzzaman M, Lynn D, van der Loo JC, Malik P. Purification of baculovirus vectors using heparin affinity chromatography. Mol Ther Methods Clin Dev 2016; 3:16071 [View Article] [PubMed]
     [Google Scholar]
  78. Felberbaum RS. The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. Biotechnol J 2015; 10:702–714 [View Article] [PubMed]
     [Google Scholar]
  79. Lu H-Y, Chen Y-H, Liu H-J. Baculovirus as a vaccine vector. Bioengineered 2012; 3:271–274 [View Article] [PubMed]
     [Google Scholar]
  80. Luo W-Y, Shih Y-S, Hung C-L, Lo K-W, Chiang C-S et al. Development of the hybrid Sleeping Beauty: baculovirus vector for sustained gene expression and cancer therapy. Gene Ther 2012; 19:844–851 [View Article] [PubMed]
     [Google Scholar]
  81. Hu L, Li Y, Ning Y-J, Deng F, Vlak JM et al. The Major Hurdle for Effective Baculovirus Transduction into Mammalian Cells Is Passing Early Endosomes. J Virol 2019; 93:e00709-19 [View Article] [PubMed]
     [Google Scholar]
  82. Oggu GS, Sasikumar S, Reddy N, Ella KKR, Rao CM et al. Gene delivery approaches for mesenchymal stem cell therapy: strategies to increase efficiency and specificity. Stem Cell Rev Rep 2017; 13:725–740 [View Article] [PubMed]
     [Google Scholar]
  83. Zhang X, Xu K, Ou Y, Xu X, Chen H. Development of a baculovirus vector carrying a small hairpin RNA for suppression of sf-caspase-1 expression and improvement of recombinant protein production. BMC Biotechnol 2018; 18:24 [View Article] [PubMed]
     [Google Scholar]
  84. Zhang X, Zhao K, Lan L, Shi N, Nan H et al. Improvement of protein production by engineering a novel antiapoptotic baculovirus vector to suppress the expression of sf-caspase-1 and tn-caspase-1. Biotechnol Bioeng 2021; 118:2977–2989 [View Article]
     [Google Scholar]
  85. Bai S, Jin D, Jiang Y, Chen F, Cheng W et al. Development of a recombinant baculovirus with dual effects to mediate V-atpase interference by RNA in the fall armyworm spodoptera frugiperda. J Pest Sci 20042023
     [Google Scholar]
  86. Crespo-Barreda A, Encabo-Berzosa MM, González-Pastor R, Ortíz-Teba P, Iglesias M et al. Viral and nonviral vectors for in vivo and ex vivo gene therapies. Transl Regen Med to Clin 2016155–177 [View Article]
     [Google Scholar]
  87. Miner JN, Hruby DE. Vaccinia virus: a versatile tool for molecular biologists. Trends Biotechnol 1990; 8:20–25 [View Article] [PubMed]
     [Google Scholar]
  88. Gränicher G, Tapia F, Behrendt I, Jordan I, Genzel Y et al. Production of modified vaccinia ankara virus by intensified cell cultures: A comparison of platform technologies for viral vector production. Biotechnol J 2021; 16: Epub ahead of print 1 January 2021 [View Article] [PubMed]
     [Google Scholar]
  89. Lei W, Wang S, Yang C, Huang X, Chen Z et al. Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma. Sci Rep 2016; 6:1–11 [View Article]
     [Google Scholar]
  90. Ylösmäki L, Polini B, Carpi S, Martins B, Smertina E et al. Harnessing therapeutic viruses as a delivery vehicle for RNA-based therapy. PLoS One 2019; 14:e0224072 [View Article] [PubMed]
     [Google Scholar]
  91. Ikeda Y, Makino A, Matchett WE, Holditch SJ, Lu B et al. A novel intranuclear RNA vector system for long-term stem cell modification. Gene Ther 2016; 23:256–262 [View Article] [PubMed]
     [Google Scholar]
  92. Fujino K, Yamamoto Y, Daito T, Makino A, Honda T et al. Generation of a non-transmissive Borna disease virus vector lacking both matrix and glycoprotein genes. Microbiol Immunol 2017; 61:380–386 [View Article] [PubMed]
     [Google Scholar]
  93. Daito T, Fujino K, Honda T, Matsumoto Y, Watanabe Y et al. A novel borna disease virus vector system that stably expresses foreign proteins from an intercistronic noncoding region. J Virol 2011; 85:12170–12178 [View Article] [PubMed]
     [Google Scholar]
  94. Komatsu Y, Tomonaga K. Reverse genetics approaches of Borna disease virus: applications in development of viral vectors and preventive vaccines. Curr Opin Virol 2020; 44:42–48 [View Article] [PubMed]
     [Google Scholar]
  95. Schneider U, Ackermann A, Staeheli P. A Borna disease virus vector for expression of foreign genes in neurons of rodents. J Virol 2007; 81:7293–7296 [View Article] [PubMed]
     [Google Scholar]
  96. Johansson M, Berg M, Berg AL. Humoral immune response against Borna disease virus (BDV) in experimentally and naturally infected cats. Vet Immunol Immunopathol 2002; 90:23–33 [View Article]
     [Google Scholar]
  97. Stitz L, Rott R. Borna disease virus (bornaviridae). Encycl Virol 1999167–173 [View Article]
     [Google Scholar]
  98. Li J, Arévalo MT, Zeng M. Engineering influenza viral vectors. Bioengineered 2013; 4:9–14 [View Article]
     [Google Scholar]
  99. Dadonaite B, Gilbertson B, Knight ML, Trifkovic S, Rockman S et al. The structure of the influenza A virus genome. Nat Microbiol 2019; 4:1781–1789 [View Article] [PubMed]
     [Google Scholar]
  100. Ghedin E, Sengamalay NA, Shumway M, Zaborsky J, Feldblyum T et al. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 2005; 437:1162–1166 [View Article] [PubMed]
     [Google Scholar]
  101. Li X, Fu Z, Liang H, Wang Y, Qi X et al. H5N1 influenza virus-specific miRNA-like small RNA increases cytokine production and mouse mortality via targeting poly(rC)-binding protein 2. Cell Res 2018; 28:157–171 [View Article] [PubMed]
     [Google Scholar]
  102. Izzard L, Dlugolenski D, Xia Y, McMahon M, Middleton D et al. Enhanced immunogenicity following miR-155 incorporation into the influenza A virus genome. Virus Res 2017; 235:115–120 [View Article] [PubMed]
     [Google Scholar]
  103. Izzard L, Ye S, Jenkins K, Xia Y, Tizard M et al. miRNA modulation of SOCS1 using an influenza A virus delivery system. J Gen Virol 2014; 95:1880–1885 [View Article] [PubMed]
     [Google Scholar]
  104. Borgohain MP, Haridhasapavalan KK, Dey C, Adhikari P, Thummer RP. An insight into DNA-free reprogramming approaches to generate integration-free induced pluripotent stem cells for prospective biomedical applications. Stem Cell Rev Rep 2019; 15:286–313 [View Article] [PubMed]
     [Google Scholar]
  105. Nakanishi M, Otsu M. Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine. Curr Gene Ther 2012; 12:410–416 [View Article] [PubMed]
     [Google Scholar]
  106. Saga K, Kaneda Y. Oncolytic Sendai virus-based virotherapy for cancer: recent advances. Oncolytic Virother 2015; 4:141–147 [View Article] [PubMed]
     [Google Scholar]
  107. Tiwari A, Gautam A, Bhat S, Malik YS. Advances and applications of vectored vaccines in animal diseases. Genomics Biotechnol Adv Vet Poultry 2020361–380 [View Article]
     [Google Scholar]
  108. Tong L, Liu D, Cao Z, Zheng N, Mao C et al. Research status and prospect of non-viral vectors based on siRNA: a review. Int J Mol Sci 2023; 24:3375 [View Article] [PubMed]
     [Google Scholar]
  109. Ura T, Okuda K, Shimada M. Developments in viral vector-based vaccines. Vaccines 2014; 2:624–641 [View Article] [PubMed]
     [Google Scholar]
  110. Miyamoto K, Akiyama M, Tamura F, Isomi M, Yamakawa H et al. Direct in vivo reprogramming with sendai virus vectors improves cardiac function after myocardial infarction. Cell Stem Cell 2018; 22:91–103 [View Article] [PubMed]
     [Google Scholar]
  111. Munis AM, Bentley EM, Takeuchi Y. A tool with many applications: vesicular stomatitis virus in research and medicine. Expert Opin Biol Ther 2020; 20:1187–1201 [View Article] [PubMed]
     [Google Scholar]
  112. Sakuda T, Kubo T, Johan MP, Furuta T, Sakaguchi T et al. Development of an oncolytic recombinant vesicular stomatitis virus encoding a tumor-suppressor microRNA. Anticancer Res 2020; 40:6319–6325 [View Article] [PubMed]
     [Google Scholar]
  113. Shoji J, Tanihara Y, Uchiyama T, Kawai A. Preparation of virosomes coated with the vesicular stomatitis virus glycoprotein as efficient gene transfer vehicles for animal cells. Microbiol Immunol 2004; 48:163–174 [View Article] [PubMed]
     [Google Scholar]
  114. Izumida M, Togawa K, Hayashi H, Matsuyama T, Kubo Y. Production of vesicular stomatitis virus glycoprotein-pseudotyped lentiviral vector is enhanced by ezrin silencing. Front Bioeng Biotechnol 2020; 8:368 [View Article]
     [Google Scholar]
  115. Li M, Husic N, Lin Y, Snider BJ. Production of lentiviral vectors for transducing cells from the central nervous system. JoVE 2012 [View Article]
     [Google Scholar]
  116. Hastie E, Grdzelishvili VZ. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol 2012; 93:2529–2545 [View Article]
     [Google Scholar]
  117. Cobleigh MA, Bradfield C, Liu Y, Mehta A, Robek MD. The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate. J Virol 2012; 86:4253–4261 [View Article]
     [Google Scholar]
  118. Holman DH, Wang D, Woraratanadharm J, Dong JY. Viral vectors. Vaccines Biodefense Emerg Neglected Dis 200977–91 [View Article]
     [Google Scholar]
  119. Sakuda T, Kubo T, Johan MP, Furuta T, Sakaguchi T et al. Oncolytic effect of a recombinant vesicular stomatitis virus encoding a tumor-suppressor microRNA in an osteosarcoma mouse model. Anticancer Res 2023; 43:1185–1191 [View Article] [PubMed]
     [Google Scholar]
  120. Wang Q, Vossen A, Ikeda Y, Devaux P. Measles vector as a multigene delivery platform facilitating iPSC reprogramming. Gene Ther 2019; 26:151–164 [View Article]
     [Google Scholar]
  121. Frantz PN, Teeravechyan S, Tangy F. Measles-derived vaccines to prevent emerging viral diseases. Microbes Infect 2018; 20:493–500 [View Article] [PubMed]
     [Google Scholar]
  122. Mühlebach MD. Vaccine platform recombinant measles virus. Virus Genes 2017; 53:733–740 [View Article] [PubMed]
     [Google Scholar]
  123. Hörner C, Schürmann C, Auste A, Ebenig A, Muraleedharan S et al. A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. Proc Natl Acad Sci U S A 2020; 117:32657–32666 [View Article] [PubMed]
     [Google Scholar]
  124. Lévy C, Amirache F, Girard-Gagnepain A, Frecha C, Roman-Rodríguez FJ et al. Measles virus envelope pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without precedent. Blood Adv 2017; 1:2088–2104 [View Article] [PubMed]
     [Google Scholar]
  125. Vamva E, Ozog S, Verhoeyen E, James RG, Rawlings DJ et al. An optimized measles virus glycoprotein-pseudotyped lentiviral vector production system to promote efficient transduction of human primary B cells. STAR Protoc 2022; 3:101228 [View Article] [PubMed]
     [Google Scholar]
  126. Atkins GJ, Fleeton MN, Sheahan BJ. Therapeutic and prophylactic applications of alphavirus vectors. Expert Rev Mol Med 2008; 10:e33 [View Article] [PubMed]
     [Google Scholar]
  127. Dan J, Nie L, Jia X, Xu C, Cai J et al. Visualization of the oncolytic alphavirus M1 life cycle in cancer cells. Virol Sin 2021; 36:655–666 [View Article] [PubMed]
     [Google Scholar]
  128. Lansford R. Engineering viruses for CNS studies. Encycl Neurosci 20091059–1068
     [Google Scholar]
  129. Sung YK, Kim SW. Recent advances in the development of bio-reducible polymers for efficient cancer gene delivery systems. Cancer Med J 2019; 2:6–13 [PubMed]
     [Google Scholar]
  130. Ehrengruber MU. Alphaviral vectors for gene transfer into neurons. Mol Neurobiol 2002; 26:183–201 [View Article] [PubMed]
     [Google Scholar]
  131. Lundstrom K. Alphaviruses in gene therapy. Viruses 2015; 7:2321–2333 [View Article] [PubMed]
     [Google Scholar]
  132. Lundstrom K. Alphavirus-based vaccines. Viruses 2014; 6:2392–2415 [View Article] [PubMed]
     [Google Scholar]
  133. Lundstrom K. Generation of recombinant alphaviral vectors. Cold Spring Harb Protoc 2012; 2012:825–831 [View Article] [PubMed]
     [Google Scholar]
  134. Uhlirova M, Foy BD, Beaty BJ, Olson KE, Riddiford LM et al. Use of Sindbis virus-mediated RNA interference to demonstrate a conserved role of Broad-Complex in insect metamorphosis. Proc Natl Acad Sci U S A 2003; 100:15607–15612 [View Article] [PubMed]
     [Google Scholar]
  135. Scheiman J, Tseng JC, Zheng Y, Meruelo D. Multiple functions of the 37/67-kd laminin receptor make it a suitable target for novel cancer gene therapy. Mol Ther 2010; 18:63–74 [View Article] [PubMed]
     [Google Scholar]
  136. Ramachandran M, Yu D, Dyczynski M, Baskaran S, Zhang L et al. Safe and effective treatment of experimental neuroblastoma and glioblastoma using systemically delivered triple microRNA-detargeted oncolytic semliki forest virus. Clin Cancer Res 2017; 23:1519–1530 [View Article] [PubMed]
     [Google Scholar]
  137. Neddermeyer AH, Hultenby K, Paidikondala M, Schuchman RM, Bidokhti MRM. Investigating tick-borne flaviviral-like particles as a delivery system for gene therapy. Curr Ther Res Clin Exp 2018; 88:8–17 [View Article] [PubMed]
     [Google Scholar]
  138. Pijlman GP, Suhrbier A, Khromykh AA. Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther 2006; 6:135–145 [View Article] [PubMed]
     [Google Scholar]
  139. Harvey TJ, Liu WJ, Wang XJ, Linedale R, Jacobs M et al. Tetracycline-inducible packaging cell line for production of flavivirus replicon particles. J Virol 2004; 78:531–538 [View Article] [PubMed]
     [Google Scholar]
  140. Usme-Ciro JA, Campillo-Pedroza N, Almazán F, Gallego-Gomez JC. Cytoplasmic RNA viruses as potential vehicles for the delivery of therapeutic small RNAs. Virol J 2013; 10:1–10 [View Article] [PubMed]
     [Google Scholar]
  141. Lundstrom K. Viral Vectors in Gene Therapy: Where Do We Stand in 2023?. Viruses 2023; 15:698 [View Article] [PubMed]
     [Google Scholar]
  142. Bavia L, Mosimann ALP, Aoki MN, Duarte Dos Santos CN. A glance at subgenomic flavivirus RNAs and microRNAs in flavivirus infections. Virol J 2016; 13:84 [View Article] [PubMed]
     [Google Scholar]
  143. Hussain M, Asgari S. MicroRNA-like viral small RNA from Dengue virus 2 autoregulates its replication in mosquito cells. Proc Natl Acad Sci U S A 2014; 111:2746–2751 [View Article] [PubMed]
     [Google Scholar]
  144. Hussain M, Torres S, Schnettler E, Funk A, Grundhoff A et al. West Nile virus encodes a microRNA-like small RNA in the 3’ untranslated region which up-regulates GATA4 mRNA and facilitates virus replication in mosquito cells. Nucleic Acids Res 2012; 40:2210–2223 [View Article] [PubMed]
     [Google Scholar]
  145. Torrecilla J, Rodríguez-Gascón A, Solinís MÁ, del Pozo-Rodríguez A. Lipid nanoparticles as carriers for RNAi against viral infections: current status and future perspectives. Biomed Res Int 2014161794 Epub ahead of print 2014 [View Article] [PubMed]
     [Google Scholar]
  146. Lee D, Liu J, Junn HJ, Lee E-J, Jeong K-S et al. No more helper adenovirus: production of gutless adenovirus (GLAd) free of adenovirus and replication-competent adenovirus (RCA) contaminants. Exp Mol Med 2019; 51:1–18 [View Article] [PubMed]
     [Google Scholar]
  147. Zaupa C, Revol-Guyot V, Epstein AL. Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum Gene Ther 2003; 14:1049–1063 [View Article] [PubMed]
     [Google Scholar]
  148. Anderson D, Harris R, Polayes D, Ciccarone V, Donahue R et al. Rapid generation of recombinant baculovirus and expression of foreign genes using the bac-to-bac baculovirus expression system. Focus 1995; 17:53–58
     [Google Scholar]
  149. Oliveira D M, Oliveira Silva S, Norma Melo M. Vaccinia virus-derived vectors in leishmaniases vaccine development. In Vaccines - Hist Futur. Epub Ahead of Print 2019 Epub ahead of print 2 October 2019 [View Article]
     [Google Scholar]
  150. Hoffmann E, Neumann G, Kawaoka Y, Hobom G, Webster RG. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000; 97:6108–6113 [View Article] [PubMed]
     [Google Scholar]
  151. Yonemitsu Y, Matsumoto T, Itoh H, Okazaki J, Uchiyama M et al. DVC1-0101 to treat peripheral arterial disease: A Phase I/IIa open-label dose-escalation clinical trial. Mol Ther 2013; 21:707–714 [View Article] [PubMed]
     [Google Scholar]
  152. Lawson ND, Stillman EA, Whitt MA, Rose JK. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 1995; 92:4477–4481 [View Article] [PubMed]
     [Google Scholar]
  153. Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M et al. Rescue of measles viruses from cloned DNA. EMBO J 1995; 14:5773–5784 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001972
Loading
Viral vectors: design and delivery for small RNA
J. Med. Microbiol. 74, 001972 (2025); https://doi.org/10.1099/jmm.0.001972
/content/journal/jmm/10.1099/jmm.0.001972
/content/journal/jmm/10.1099/jmm.0.001972
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error